written on 21.07.2020

Library > White Papers > Medicines for Europe


Contributed by Medicines for Europe

main_img

After several months of crisis, Medicines for Europe lays out some of the key lessons learned from COVID-19 for the future of pharmaceutical policy in Europe.

The COVID-19 outbreak in Europe has catalysed some long-standing issues in the functioning of pharmaceutical policy, as well as the impact this can have on patient access and hospital and pharmacy supply.

The off-patent medicines industry mobilised all efforts to ensure medicines continued to be developed, transported and supplied, in collaboration with the European Institutions, throughout the crisis. Our industry notably massively scaled up production and put in place cooperation mechanisms to tackle the colossal surge in demand for medicine


Related White Papers

Failure to Launch: Patent Abuse Blocks Access to Biosimilars for America’s Patients
Reimagining Global Health through Artificial Intelligence: The Roadmap to AI Maturity
The Current State of Patents in the North American Cannabis Industry
We use cookies to ensure that we give you the best experience on our site. For more info click here